



First Quarter 2013 Results

24 April 2013



Laboratorios Farmacéuticos Rovi, S.A. and Subsidiaries
Investor Relations



ROVI – First Quarter 2013 Results

ROVI reports an operating revenue growth of 6% and an EBITDA growth of 15%

- **Operating revenue increased by 6% to 53.8 million euros in the three-month period ended 31 March 2013, driven by the strength of the specialty pharmaceutical business, where sales rose 7%, despite the drop of 13% and 18% experienced by the Spanish pharmaceutical market in January and February 2013 respectively, and by the toll manufacturing business, which grew by 2%.**
- **ROVI expects to grow operating revenue from mid to high single digit for 2013, despite the impact of the latest package of measures and the Spanish pharmaceutical market decrease of 13% expected for 2013 according to Farmaindustria¹, the Spanish Pharmaceutical Association.**
- **Sales of Bemiparin increased by 13% to 16.7 million euros and sales of Corlontor, from Servier, grew by 28% in the three-month period ended 31 March 2013.**
- **In January 2011, ROVI started the marketing of Absorcol®, whose active principle is ezetimibe, and Vytorin®, which combines two active principles, ezetimibe and simvastatin, the first of the five licenses of Merck Sharp & Dohme (MSD), in Spain. Sales of Absorcol® and Vytorin® increased by 38% to 3.8 million euros in the first quarter of 2013.**
- **EBITDA increased by 15% to 7.6 million euros in the three-month period ended 31 March 2013, compared to the same period of the previous year, reflecting a 1.2 percentage points rise in the EBITDA margin to 14.1% in the first quarter of 2013 up from 12.9% in the same period of the previous year.**
- **Net profit increased by 2% to 5.3 million euros in the three-month period ended 31 March 2013, compared to the same period of the previous year.**
- **ROVI will propose to the Shareholders General Meeting a dividend of 0.1366 euros per share on 2012 earnings. This proposed dividend would mean an increase of 8% compared to the dividend on 2011 earnings.**



Madrid (Spain), 24 April 2013, 8:00 AM CET - ROVI released today its financial results for the three months ending on 31 March 2013.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said that *"in the first quarter of 2013, we reached a significant 6% operating revenue growth driven by the strength of two of our pillars of growth, our specialty pharmaceutical area and our toll manufacturing area. We achieved this excellent operating revenue growth despite the drop of 13% and 18% experienced by the Spanish pharmaceutical market in January and February 2013 respectively. In addition, according to Farmaindustria¹, the Spanish Pharmaceutical Association, the Spanish pharmaceutical market will fall 13% in 2013. Despite the difficult situation that the pharmaceutical industry is going through, we forecast to continue growing.*

Once again Bemiparin led the growth with a 13% increase in sales. Bemiparin sales in Spain rose 11% and outside Spain grew by 15%, highlighting the continued internationalisation of our flagship product as one of the Company's growth engines in the medium term. Furthermore, the agreement with MSD allows us to strengthen our toll manufacturing area, as we have already reflected in the results for the last three years, as well as our specialty pharmaceutical area, as we showed with the launch, in January 2011, of Vytarin and Absorcol, the first of the five licenses from MSD that will contribute to our growth in the coming years. This launch required a significant investment effort in human capital in 2011 in order to address new prescribers. We expect this effort to result in a significant sales growth and operating leverage in the coming years. In addition, the MSD agreement will allow us to launch four additional new products in the next 7 years, underpinning our belief in the sustainability of the long term outlook for the company. ROVI's R&D pipeline continues to hold strong potential to drive the company's growth in future years. We are very excited with the potential of the ISM technology, especially with the Risperidone-ISM® project development, whose phase I/II studies are being started along 2013. This gives us the confidence and security to continue, not only with our development of Risperidone ISM, but also with the development of other candidates with which we are already in an advanced pre-clinical phase".

1. <http://www.coib.org/uploadsBO/Generica/Documents/24-10.PDF>



1. Financial highlights

<i>€ million</i>	Q1 2013	Q1 2012	Growth	% Growth
Operating revenue	53.8	50.9	2.8	6%
Other income	0.3	0.3	0.0	(1%)
Total revenue	54.1	51.3	2.8	6%
Raw materials used and changes in inventories	(22.4)	(20.0)	(2.4)	12%
Gross profit	31.7	31.3	0.4	1%
<i>% margin</i>	<i>59.0%</i>	<i>61.4%</i>		(2.4pp)
R&D expenses	(2.6)	(2.3)	(0.3)	12%
Other SG&A	(21.5)	(22.3)	0.8	(4%)
Share of loss/profit of joint venture	0.0	0.0	0.0	(100%)
EBITDA	7.6	6.6	1.0	15%
<i>% margin</i>	<i>14.1%</i>	<i>12.9%</i>		1.2pp
EBIT	6.0	5.4	0.6	11%
<i>% margin</i>	<i>11.1%</i>	<i>10.6%</i>		0.5pp
Net profit	5.3	5.3	0.1	2%

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

The consolidated financial statements of Grupo ROVI for the first quarter of 2013 and the comparative information for 2012 (balance sheet) and for the first quarter of 2012 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1).



2. Performance of the Group

Operating revenue increased by 6% to 53.8 million euros in the three-month period ended 31 March 2013, driven by the strength of the specialty pharmaceutical business, where sales rose 7%, despite the drop of 13% and 18% experienced by the Spanish pharmaceutical market in January and February 2013 respectively, and by the toll manufacturing business, which grew by 2%.

Sales of **prescription-based pharmaceutical products** rose 7% to 30.7 million euros in the three-month period ended 31 March 2013. In September 2012, ROVI and UCB reached an agreement under which they ended their commercial relationship with regards to Cimzia. Since 15th of June 2010, Cimzia had been jointly co-promoted in Spain by ROVI and UCB. Excluding the impact of Cimzia co-promotion in the first quarter of 2012, sales of prescription-based pharmaceutical products increased by 9% in the first quarter of 2013.

ROVI's low molecular weight heparin (LMWH), **Bemiparin**, maintained a growth rate, with sales up 13% to 16.7 million euros. Sales of Bemiparin in Spain (**Hibor®**) increased by 11% to 10.3 million euros, while international sales rose 15% to 6.4 million euros in the first quarter of 2013 supported by the increased presence of Bemiparin, through strategic alliances, in countries where it was already present, and by the launch of the product in two new countries, South Korea and Lebanon, during the first quarter of 2013.

Sales of **Vytorin®** and **Absorcol®**, the first of the five licenses of MSD, launched in January 2011, increased by 38% to 3.8 million euros in the three-month period ended 31 March 2013.

Sales of **Corlontor®**, a specialty product for stable angina and chronic heart failure from Laboratoires Servier, rose 28% to 2.7 million euros in the three-month period ended 31 March 2013.

Sales of **Thymanax®**, an innovative antidepressant from Laboratoires Servier, launched in March 2010 and for which ROVI has a co-marketing agreement covering Spain, decreased by 5% to 2.7 million euros in the three-month period ended 31 March 2013 impacted by the last measures package introduced by the Spanish Government in April 2012.

Sales of **Exxiv®**, a selective COX-2 inhibitor from Merck Sharp & Dohme (MSD), decreased by 8% to 1.8 million euros in the three-month period ended 31 March 2013, mainly due to a fall of the COX-2 market.

Sales of **Osseor®**, a specialty product for the treatment of postmenopausal osteoporosis from Laboratoires Servier, decreased by 26% to 1.3 million euros in the first quarter of 2013.



On 20th of April of 2012, the Spanish government announced a new package of measures in order to achieve savings of more than 7 billion euros in healthcare expenditure. These new measures were published on the official state gazette on the 24th of April (see <http://www.boe.es/boe/dias/2012/04/24/pdfs/BOE-A-2012-5403.pdf>).

Among these new measures, (i) the exclusion of some drugs from reimbursement and (ii) the pharmaceutical copayment, became more relevant. The list of drugs excluded from reimbursement was published on the 29th of June (see <http://www.msssi.gob.es/profesionales/farmacia/pdf/ProyectoResolucionExclusion.pdf>), without any material impact for the ROVI product portfolio, and the pharmaceutical copayment was effective from the 1st of July. The introduction of the latest package of measures, especially of the pharmaceutical copayment, meant a monthly pharmaceutical expenditure drop of above 20% on average from July to December 2012 and the number of prescriptions was reduced monthly by 15% on average in the same period. This negative trend continued in the first quarter of 2013; the Spanish pharmaceutical market decreased by 13% and 18% in January and February respectively. In addition, according to Farmaindustria¹, the Spanish Pharmaceutical Association, the Spanish pharmaceutical market will fall 13% in 2013, in line with 2012. Despite the difficult situation that the pharmaceutical industry is going through, ROVI forecasts to continue growing.

Sales of **contrast imaging agents** and other hospital products increased by 7% to 5.8 million euros in the first quarter of 2013.

Sales of **over-the-counter pharmaceutical products** declined by 9% to 1.3 million euros in the three-month period ended 31 March 2013 compared to the same period of the previous year. This was mainly as consequence of the reduction of consumption in the current Spanish economic environment.

Toll manufacturing sales increased by 2% to 15.8 million euros in the three-month period ended 31 March 2013 compared to the same period of the previous year, mainly as a result of the contribution of the injectables plant whose revenue more than doubled in the three-month period ended 31 March 2013.

Sales outside Spain remained stable at 21.7 million euros in the three-month period ended 31 March 2013 compared with the same period of the previous year. Sales outside Spain represented 40% of operating revenue in the first quarter of 2013 compared to 43% in the first quarter of 2012.

1. <http://www.coib.org/uploads/BO/Generica/Documents/24-10.PDF>



Gross profit increased by 1% to 31.7 million euros in the three-month period ended 31 March 2013, reflecting a decrease in the gross margin to 59.0% in the first quarter of 2013, from 61.4% in the first quarter of 2012, mainly as a result of:

- the increase of the production from other clients in the Frosst Ibérica facility which contributed lower margins than Merck Sharp and Dohme (MSD);
- the price reduction of the contrast imaging agents and other hospital products that did not impede the achievement of higher sales as consequence of higher volume sold; and
- a change in the guidelines for the assignment of indirect costs to the stock.

The decrease of the Bemiparin raw material cost impacted positively in the first quarter of 2013 gross margin. In the three-month period ended 31 March 2013, ROVI continued to buy Bemiparin raw material for around 35 euros per million of international units and it expects this stable trend to continue in 2013. ROVI expects to maintain 2013 gross margin in line with the 2012 figure, mainly supported by the Bemiparin raw material cost decrease and a higher contribution of the injectables toll manufacturing business.

Research and development expenses increased by 12% to 2.6 million euros in the three-month period ended 31 March 2013, reflecting ROVI investments in products that are under development.

Selling, general and administrative expenses decreased by 4% to 21.5 million euros in the first quarter of 2013, compared to the same period of the previous year, mainly as a result of (i) the reduction of the ROVI sales team due to the end of the commercial relationship with UCB regarding Cimzia in September 2012 and (ii) ROVI's strict cost control.

EBITDA increased by 15% to 7.6 million euros in the three-month period ended 31 March 2013, compared to the same period of the previous year, reflecting a 1.2 percentage points rise in the EBITDA margin to 14.1% in the first quarter of 2013 up from 12.9% in the same period of the previous year.

Depreciation and amortisation expenses increased by 35% in the three-month period ended 31 March 2013, compared to the same period of the previous year, mainly as a result of the new property plant and equipment and intangible assets purchases made during the last twelve months (see section 3.1).

EBIT increased by 11% to 6.0 million euros in the three-month period ended 31 March 2013, compared to the same period of the previous year, reflecting a 0.5 percentage points rise in the EBIT margin to 11.1% in the first quarter of 2013 up from 10.6% in the same period of the previous year.



Financial expense increased by 4% in the first quarter of 2013, compared to the same period of the previous year. The financial expense line mainly includes the implicit interests registered as a result of the recognition at fair value of the reimbursable loans, at zero interest rate, granted by Public Administration.

The **financial income** line decreased by 75% in the three-month period ended 31 March 2013, compared to the same period of the previous year, mainly as a result of lower returns on financial investments.

The **effective tax rate** was 3.1% in the first quarter of 2013 compared with 0.5% in the first quarter of 2012. This favourable effective tax rate is due to the deduction of existing research and development expenses and the capitalisation of existing negative tax bases resulting from the Frosst Ibérica integration. Frosst Ibérica negative tax bases amounted to 62.8 million euros as of 31 December 2012, of which 5.3 million euros will be used in the 2012 income tax and 1.5 million euros to be used in the first quarter of 2013.

On 30th March 2012, the Spanish Government approved by law a package of tax measures (<http://www.boe.es/boe/dias/2012/03/31/pdfs/BOE-A-2012-4441.pdf>) in order to reduce Spanish public deficit. Among these tax measures, the elimination of the freedom of depreciation incentive and the reduction of the deductions limits affected first quarter 2013 ROVI Group income statement. In addition, these measures will affect ROVI income tax payable rate.

In addition, on 13th July 2012, the Spanish Government approved by law a new package of tax measures (<http://www.boe.es/boe/dias/2012/07/14/pdfs/BOE-A-2012-9364.pdf>) in order to guarantee budgetary stability and to promote competitiveness. Among these new tax measures, the limitation of the negative tax bases to be offset, which was reduced to 25% from 50%, and the tax rate increase for the payment on account, from 27% to 29% for ROVI, as well as the minimum disbursement for this payment, from 8% to 12%, will affect ROVI income tax payable rate.

As a consequence of the signature, on 15 February 2013, of the Conformity Assessment arising from the corporate income tax inspection of ROVI group for the periods 2007 and 2008, the Group recorded a corporate income tax expense of 109 thousand euros. On the same date, the VAT tax inspection of ROVI group for the same periods ended without any payments to be assumed.

Net profit increased by 2% to 5.3 million euros in the three-month period ended 31 March 2013, compared to the same period of the previous year.



ROVI will pay a **dividend** of 0.1366 euros per share on 2012 earnings if the Shareholders General Meeting approves the application of the 2012 profit, under proposal of ROVI Board of Directors. This proposed dividend would mean an increase of 8% compared to the dividend on 2011 earnings. In addition, this dividend would imply the pay-out of 35% of consolidated net profit for 2012.

Javier López-Belmonte Encina, Chief Financial Officer of ROVI, said that, *"we are satisfied with the results for the first quarter of 2013. Operating revenue increased by 6% from the previous year. This was in line with expectations despite the difficulties in the economic and regulatory environments. We attribute this out-performance to the strength of our leading products, which continue to gain share in their various market segments, and to the contribution of the toll manufacturing business. EBITDA margin increased in the first quarter of 2013 mainly as a result of the operating leverage contributed by our last product launches. We expect to keep EBITDA margin expansion in 2013. It is very gratifying to witness the growth in the strength of our balance sheet and our excellent capacity to generate cash, which allow us to finance organic growth through the launch of new products, such as Vytorin and Absorcol, and to be in a strong position to benefit in the current operating environment as we will pay attention to potential opportunities to expand our sales base and better the utilisation of our asset base"*.

3. Balance Sheet items

3.1 Capital expenditure

ROVI invested 1.5 million euros in the three-month period ended 31 March 2013, compared to 1.9 million euros in the same period of the previous year. Of this amount:

- 0.5 million euros corresponds to investment capex related to the injectables facility mainly in order to prepare the plant for the development of the ISM project, versus 0.3 million euros in the first quarter of 2012; and
- 1.0 million euros corresponds to expenditure on maintenance, versus 0.7 million euros in the first quarter of 2012.
- 0.2 million euros and 0.7 million euros were invested in the Alcalá and Granada facilities respectively in the first quarter of 2012.

ROVI expects capital expenditure for 2013 to be in line with the 2012 figure as a result of the preparation of the injectables facility for the development of the ISM study Phase II.



3.2 Debt

As of 31 March 2013, ROVI had total debt of 38.1 million euros. Debt with public administration represented, as of 31 March 2013, 72% of total debt and 94% of total debt is 0% interest rate debt.

<i>In thousand euros</i>	31 March 13	31 December 12
Loans from banks	2,337	2,813
Debt with public administration	27,596	27,505
Debt from purchase of shares	8,155	8,072
Total	38,088	38,390

The debt from purchase of shares registered as of 31 March 2013 corresponds to the outstanding payment related to the Frosst Ibérica acquisition, which includes the payment of 1.4 million euros for the Frosst Ibérica shares acquisition (the first three payments of 0.7 million euros each one were executed on 31 March 2010, 31 March 2011 and 20 April 2012) and the payment of 6.8 million euros for the Frosst Ibérica working capital (the first two payments of 3.2 million euros each one were executed on 31 March 2011 and on 12 April 2012). On April 2, 2013, 4.2 million euros related to this debt were paid and the outstanding debt of 4.0 million euros will be paid on 31 March 2014.

3.3 Free cash flow

Free cash flow (net cash generated (used) from operating activities plus/minus property, plant and equipment and intangible assets purchases/sales plus interest received) increased to 4.7 million euros in the first quarter of 2013 from (3.2) million euros in the first quarter of 2012, mainly as a result of an inventories decrease of 4.7 million euros in the first quarter of 2013 compared to an inventories increase of 3.2 million euros in the first quarter of 2012 which is mainly due to a lower amount of Bemiparin stock in the first quarter of 2013 compared to the first quarter of 2012.

3.4 Net and gross cash position

As of 31 March 2013, ROVI had a gross cash position of 50.6 million euros, compared to 45.9 million euros as of 31 December 2012, and a net cash position (financial assets and cash minus short term and long term debt) of 12.5 million euros, compared to 7.5 million euros as of 31 December 2012, providing it with a high level of financial flexibility.



3.5 Working capital

The increase in working capital in the first quarter of 2013 was mainly due to a cash increase of 5.6 million euros. Inventories decreased by 4.7 million euros in the first quarter of 2013. The "trade and other receivables" item increased by 5.3 million euros and the "trade and other payable" item decreased by 2.7 million euros.

In April 2013, the Spanish Government announced a new "Suppliers Plan" (http://www.minhap.gob.es/es-es/prensa/en%20portada/2013/Paginas/20130402_larazon.aspx) in order to cancel outstanding debts with Local Entities and Regions suppliers. According to the Government statement, this Plan will be related to the fulfillment of the Default Guideline which forces them to pay suppliers within 30 days. ROVI expects to cash between 11 million euros to 14 million euros from this Plan, considering the pending invoices due for collection from the Autonomous Regions by 31st December 2012, in the second half of 2013.

4. Guidance for 2013

ROVI expects **to grow operating revenue from mid to high single digit for the full year 2013**, in spite of (i) the impact of the latest package of measures, approved by the Spanish Government on 20 April 2012, which was effective on the 1st of July in order to obtain savings of more than 7 billion euros in healthcare expenditure, and (ii) the decrease of the Spanish pharmaceutical market of 13% expected for 2013, according to Farmaindustria¹, the Spanish Pharmaceutical Association.

ROVI expects its growth drivers to be Bemiparin, its existing portfolio of specialty pharmaceuticals, last launches such as Vytorin, Absorcol and Thymanax, new product distribution licenses and new customers in the toll manufacturing area.

5. Research and Development update

ROVI's R&D projects are mainly focused on the ISM® platform, which is an own proprietary drug delivery system aimed to improve patients' therapeutic compliance. The most advanced candidate is Risperidone ISM®, a second-generation antipsychotic drug.

As it has previously been informed, the ISM technology has already been validated after obtaining positive results from a "proof of concept" phase I study on healthy subjects. In 2012, ROVI has obtained scientific advice from the FDA on the drug development program of

1. <http://www.coib.org/uploadsBO/Generica/Documents/24-10.PDF>



Risperidone ISM®; in addition, during last year and the first quarter of 2013 ROVI has undertaken important investments in order to build in Madrid a manufacturing plant for new medicines using the ISM technology; this will be equipped with a very innovative, and unique in its class, machinery for filling solid compounds in syringes under good manufacturing practices. Thanks to these new facilities, ROVI will be prepared to supply with quality and agility the needed samples for carrying out the clinical trials within the next years, and in the future, the industrial production of commercial batches.

Patients' enrolment for additional Phase I and II studies with Risperidone ISM® are being started along 2013. Besides, the ISM® preclinical research on two additional compounds is progressing well. Accordingly, the first clinical study with Paliperidone ISM® (another second-generation antipsychotic drug) and Letrozole ISM® (an aromatase inhibitor) are planned to be started by the first and second half of 2014, respectively.

On the other hand, ROVI informs that has recently patented a multilayer technology platform which will be initially used to develop uretral catheters. The development of this technology is based on the use of polymer layers that bioerode under the influence of bacterial metabolism. This erosion provides important advantages over the state of the art technologies, reducing bacterial adhesion on the luminal surface and facilitating biofilm elimination and formation of encrustations that lead to catheter blockage; consequently they could increase patient's quality of life, reduce the use of antibiotics and catheter substitutions due to blockage and thus, also decrease morbidity and hospitalization associated to the use of these devices.

In 2012, ROVI has developed several polymeric compositions, performed many microbiological trials and started scale-up processes studies. ROVI expects to obtain the first prototypes for the initiation of in vivo efficacy studies in animals in 2013.

The development of this innovative research line will provide ROVI with the ability to extend company's portfolio in the medical devices field in a competitive way, as the technology can be also used in the development of other medical devices like nasogastric tubes or in odontology, serving as a technology platform for other developments.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and



alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM™ technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es

For further enquiries, please contact:

Juan López-Belmonte Encina
Chief Executive Officer
913756235
jlopez-belmonte@rovi.es
www.rovi.es

Javier López-Belmonte Encina
Chief Financial Officer
913756266
javierbelmonte@rovi.es
www.rovi.es

Marta Campos Martínez
Investor Relations
912444422
mcampos@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or



implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except in case of substantive changes. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date subsequent to the date of this press release.



APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2013 AND 31 DECEMBER 2012

(Thousand of euros)

	31 March 2013	31 December 2012
ASSETS		
Non-current assets		
Property, Plant and Equipment	53,724	53,791
Intangible assets	3,155	3,176
Deferred tax assets	6,544	6,073
Available-for-sale financial assets	27,241	28,148
Trade and other receivables	133	133
	90,797	91,321
Current assets		
Inventories	51,484	56,225
Trade and other receivables	59,695	54,377
Current income tax assets	823	3,855
Cash and cash equivalents	22,193	16,585
	134,195	131,042
Total assets	224,992	222,363



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF 31 MARCH 2013 AND 31 DECEMBER 2012

(Thousand of euros)

	31 March 2013	31 December 2012
EQUITY		
Capital and reserves attributable to shareholders of the company		
Share capital	3,000	3,000
Legal reserve	600	600
Treasury shares	(1,540)	(2,060)
Retained earnings and voluntary reserves	125,326	105,692
Profit for the period	5,338	19,514
Reserve for available-for-sale assets	(245)	(299)
Total equity	132,479	126,447
LIABILITIES		
Non-current liabilities		
Financial debt	28,749	29,135
Deferred income tax liabilities	3,103	3,256
Non-current deferred revenue	8,154	8,393
	40,006	40,784
Current liabilities		
Trade and other payables	37,141	39,878
Financial debt	9,339	9,255
Current deferred revenue	4,348	4,348
Provisions for other liabilities and charges	1,679	1,651
	52,507	55,132
Total liabilities	92,513	95,916
Total equity and liabilities	224,992	222,363



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS FOR THE THREE-MONTH PERIODS ENDED 31
MARCH 2013 AND 31 MARCH 2012

(Thousand of euros)

	Three-month periods ended 31 March	
	2013	2012
Revenue	53,781	50,947
Changes in inventories	(4,741)	3,249
Raw materials and consumables used	(18,445)	(23,250)
Employee benefit expenses	(12,871)	(12,406)
Other operating expenses	(10,463)	(12,227)
Result from joint venture	-	(42)
Depreciation, amortisation and impairment charges	(1,594)	(1,185)
Recognition of government grants on non financial non-current assets and other	321	323
OPERATING PROFIT	5,988	5,409
Finance income	111	442
Finance costs	(589)	(568)
FINANCE COSTS - NET	(478)	(126)
PROFIT BEFORE INCOME TAX	5,510	5,283
Income tax	(172)	(26)
PROFIT FOR THE PERIOD	5,338	5,257



LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR THE THREE-MONTH PERIODS ENDED 31
MARCH 2013 AND 31 MARCH 2012

(Thousand of euros)

	Three-month periods	
	2013	2012
Cash flows from operating activities		
Profit before income tax	5,510	5,283
Adjustments for non-monetary transactions:		
Amortisation	1,594	1,185
Interest income	(111)	(442)
Gains or losses on derecognition of financial assets and liabilities	-	21
Interest expense	589	568
Net changes in provisions	28	8
Grant for non-financial fixed assets and distribution licence income	(283)	(201)
Changes in working capital		
Trade and other receivables	(5,419)	(2,839)
Inventories	4,741	(3,249)
Trade and other payables	(2,757)	(3,681)
Other collections and payments		
Interest paid	(13)	33
Income tax cash flow	2,213	1,639
Net cash generated (used) from operating activities	6,092	(1,675)
Cash flows from investing activities		
Purchases of intangible assets	(120)	(114)
Purchases of property, plant and equipment	(1,386)	(1,812)
Purchases of available-for-sale financial assets	-	(1,000)
Proceeds from sale of available-for-sale financial assets	957	2,019
Reduction in cash from sale of Alentia Biotech	-	(10,278)
Interest received	111	442
Net cash generated (used) in investing activities	(438)	(10,743)
Cash flows from financing activities		
Repayments of financial debt	(1,313)	(569)
Proceeds from financial debt	627	1,000
Purchase of treasury shares	(731)	(89)
Reissue of treasury shares	1,371	104
Net cash generated in financing activities	(46)	446
Net (decrease)/increase in cash and cash equivalents	5,608	(11,972)
Cash and cash equivalents at beginning of the period	16,585	49,491
Cash and cash equivalents at end of the period	22,193	37,519